Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
Cancer2014Vol. 121(2), pp. 311–319
Citations Over TimeTop 10% of 2014 papers
Ole‐Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay, Lipika Goyal, Michael Davis, Marina D. Kaymakcalan, Jonathan S. Williams
Abstract
Preexisting hypertension, age, and BMI identify patients at risk for significant anti-VEGF therapy-induced BP elevation. Hypertension appears to be a clinical biomarker of efficacy of anti-VEGF therapies in a broad range of malignancies.
Related Papers
- → Benefits of pazopanib over sunitinib for renal cell carcinoma(2016)6 cited
- → Can We Translate Non-inferiority Clinical Trial into Practice? Real World Outcome of Sunitinib and Pazopanib as First Line Targeted Therapy in Metastatic Renal Cell Carcinoma: UK Centre Experience(2020)1 cited
- → Cost Comparison in the Management of the Renal Cell Carcinoma with in Spain: Pazopanib vs. Sunitinib(2016)
- → Comparison of First-line Pazopanib and Sunitinib in Metastatic Renal Cell Carcinoma: Experiences of the Urologic Cancer Centre for Research and Innovation(2019)
- → Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center(2023)